Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Angiotensin in atherosclerosis.

Valentina Kon¹, Kathy Jabs

¹Vanderbilt University Medical Center, Nashville, Tennessee 37232-2584, USA. valentina.kon@vanderbilt.edu

Current Opinion in Nephrology and Hypertension

|April 10, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

LYVE1 ectodomain shedding blunts lymphatic transmigration and clearance of macrophages during kidney injury.

JCI insight·2026

Same author

Association of rehospitalization after pediatric kidney transplantation with kidney function at 1-year posttransplant and long-term allograft failure.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025

Same author

Moving toward a better understanding of renal lymphatics: challenges and opportunities.

Pediatric nephrology (Berlin, Germany)·2025

Same author

Sodium-Directed Crosstalk Between Immune Cells and Lymphatic Vessels.

Current hypertension reports·2025

Same author

ET-3/ETBR Mediates Na<sup>+</sup>-Activated Immune Signaling and Kidney Lymphatic Dynamics.

Circulation research·2024

Same author

Myeloid Cell Glucocorticoid, Not Mineralocorticoid Receptor Signaling, Contributes to Salt-Sensitive Hypertension in Humans via Cortisol.

bioRxiv : the preprint server for biology·2024

Increased angiotensin II activity amplifies atherosclerosis by affecting lipid metabolism and plaque stability. Blocking angiotensin II may slow, stabilize, or even reverse atherosclerotic disease progression.

Area of Science:

Cardiovascular Science
Endocrinology
Vascular Biology

Background:

Angiotensin II is known to cause cardiovascular and renal disorders.
Emerging evidence highlights angiotensin II's significant role in atherosclerosis, characterized by lipid accumulation in blood vessel walls.

Purpose of the Study:

To review the role of angiotensin II in the development and progression of atherosclerotic disease.
To explore the mechanisms by which angiotensin II influences atherosclerosis.
To discuss the therapeutic potential of antagonizing angiotensin II actions in atherosclerosis.

Main Methods:

Review of recent scientific literature on angiotensin II and atherosclerosis.
Analysis of studies investigating the impact of angiotensin II on lipid metabolism and plaque stability.

Related Experiment Videos

Examination of the interplay between angiotensin II and other atherosclerosis risk factors.

Main Results:

Angiotensin II activity is elevated in atherosclerosis, and even temporary increases exacerbate the condition.
Aldosterone, a downstream hormone, also contributes to vascular damage.
Angiotensin II potentiates damage from risk factors like hypertension, hyperlipidemia, and diabetes, and directly impacts cellular processes and matrix proteins, influencing plaque development and stability.

Conclusions:

Elevated angiotensin II in atherosclerosis amplifies the disease by influencing risk factors and directly affecting lipid metabolism, vascular response to lipids, and plaque stability.
Antagonizing angiotensin II can reduce atherosclerosis progression, stabilize plaques, and potentially lead to disease regression.